Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma

Standard systemic therapy of advanced renal cell carcinoma (RCC) involves targeting angiogenesis, mainly through tyrosine kinase inhibitors (TKI) against the vascular endothelial growth factor receptor (VEGFR) pathway and targeting the immune checkpoints, namely, programmed death-1 (PD-1) or its lig...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitsogiannis, Iraklis C., Mitsogianni, Maria, Papathanassiou, Maria, Anagnostou, Maria, Tamposis, Ioannis, Mitrakas, Lampros, Samara, Maria, Tzortzis, Vassilios, Vlachostergios, Panagiotis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Codon Publications 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551369/
https://www.ncbi.nlm.nih.gov/pubmed/36310639
http://dx.doi.org/10.15586/jkcvhl.v9i3.243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551369/
https://www.ncbi.nlm.nih.gov/pubmed/36310639
http://dx.doi.org/10.15586/jkcvhl.v9i3.243

Ejemplares similares